Welcome to our dedicated page for Propanc Bio SEC filings (Ticker: PPCB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Propanc Biopharma, Inc. (PPCB) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory disclosures, including registration statements, annual and quarterly reports, and current reports on material events. As a Delaware-incorporated, Nasdaq-listed biopharmaceutical company, Propanc uses these filings to describe its proenzyme-based oncology platform, financial condition, capital structure, and key agreements.
Through documents such as the Form S-1 registration statement and periodic reports, readers can review detailed information about Propanc’s business focus on recurrent and metastatic cancer, its lead product candidate PRP, and its status as a pre-revenue development-stage enterprise. These filings discuss risk factors, use of proceeds from offerings, and the scientific and clinical context for PRP and the company’s broader pipeline, including the recombinant follow-on candidate Rec-PRP.
Current reports on Form 8-K are particularly relevant for tracking financing and corporate actions. Recent 8-K filings describe Propanc’s entry into a Securities Purchase Agreement with Hexstone Capital LLC, the creation and designation of Series C Preferred Stock, and the issuance of preferred shares and warrants in a private placement of up to $100 million. These filings outline conversion terms, ownership limitations, and amendments to the company’s certificate of incorporation.
Investors and analysts can also use this page to monitor capital structure and governance changes, including preferred stock designations and uplisting-related disclosures, as well as to cross-reference financial statements and footnotes that detail assets, liabilities, and stockholders’ equity. Real-time updates from EDGAR ensure that newly filed 10-Ks, 10-Qs, 8-Ks, and registration statements are available as they are submitted.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections, highlight key terms in offerings and preferred stock instruments, and help clarify how regulatory disclosures relate to Propanc’s clinical plans, digital asset treasury strategy, and overall risk profile.
Propanc Biopharma, Inc. is registering up to 2,000,000 shares of common stock for resale by a single selling stockholder, Hexstone Capital LLC. These shares underlie 100 initially issued shares of Series C Preferred Stock and up to 9,900 additional Series C Preferred shares issuable upon exercise of a warrant. Propanc will not receive any proceeds from the resale, but would receive cash if the warrant is exercised.
Each Series C Preferred share has a stated value of $10,000 and converts into common stock at the lesser of a fixed $5.00 per share or 85% of a market-based price, subject to a 4.99% beneficial ownership cap that may be increased to 9.99% with notice. The company previously raised approximately
Propanc is a development-stage oncology company focused on its lead anti-cancer candidate PRP for pancreatic, ovarian, and colorectal cancers, has no revenue-generating operations and an accumulated deficit, and discloses substantial doubt about its ability to continue as a going concern without additional capital. As of December 15, 2025, it had 13,364,244 common shares outstanding and would have 15,364,244 shares if all registered shares are issued and sold, and it qualifies as both a smaller reporting company and a controlled company under Nasdaq rules.
Propanc Biopharma (PPCB) filed its quarterly report for the three months ended September 30, 2025. The company reported no revenue and a net loss of $4,837,738, compared with a $354,310 loss a year ago. Operating expenses rose to $4,673,564 (from $290,790), driven mainly by administration expenses of $4,598,574, which included non‑cash items such as amortization of prepaid stock-based expenses.
Cash increased to $602,737 from $12,088, helped by financing inflows. The company completed an equity raise on August 18, 2025, selling 1,000,000 shares for $4,000,000 in gross proceeds and receiving approximately $3.3 million net. Total assets were $17,975,681, led by significant prepaid expenses, while total liabilities declined to $3,614,514 as convertible notes and related derivative balances decreased. The filing notes substantial doubt about the company’s ability to continue as a going concern. Common shares outstanding were 12,806,748 at September 30, 2025, and 13,364,244 as of November 13, 2025.
Propanc Biopharma (PPCB) closed a private placement with Hexstone Capital, receiving $1,000,099 in cash for 100 shares of Series C Preferred Stock and issuing a warrant to purchase up to 9,900 additional Series C Preferred shares at an exercise price of $10,000 per warrant share. The securities were issued under Section 4(a)(2) and Rule 506 of Regulation D.
The company also created and authorized up to 9,900 shares of Series C Preferred through a Certificate of Designation. Each preferred share has a stated amount of $10,000 and is convertible into common stock at the lesser of a fixed $5.00 per share or 85% of the lowest trading price during a defined period with a five trading day minimum and a volume condition. This brings in immediate cash and sets terms for potential future conversions and warrant exercises.
Propanc Biopharma (PPCB) entered a Securities Purchase Agreement for a private placement of a new Series C Preferred Stock class. The deal with Hexstone Capital provides for the issuance of 100 Series C Preferred shares at closing and a Warrant to purchase up to an additional 9,900 Series C Preferred shares. Each Series C Preferred share is convertible into common stock at the lesser of a fixed $5.00 per-share conversion price or 85% of the lowest trading price during a defined period tied to a holder’s conversion notice, with a five trading day minimum. The closing is conditioned on filing the Certificate of Designation for the Series C Preferred with Delaware.
Propanc Biopharma, Inc. (PPCB) reported financials highlighting severe liquidity and solvency pressures. The company recorded an accumulated deficit of $125,621,520 and net cash used in operations of $405,168. It had no cash equivalents at June 30, 2025. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern for at least twelve months.
The filing discloses a 1:60,000 Reverse Stock Split effective January 29, 2025, numerous loans and convertible notes with defaults or past due maturities, and debt-exchange transactions that settled loans for common stock (e.g., 30,000 shares issued to settle $86,248 of loans). The company lists extensive granted patents and patent validations for its proenzyme/proenzyme compositions across many jurisdictions. It completed a registered offering that produced $3.34 million net proceeds.
FAQ
What is the current stock price of Propanc Bio (PPCB)?
What is the market cap of Propanc Bio (PPCB)?
